However, such variations in HIF-1α mRNA expression in T-allele carriers, are in accordance with the large variation of leukocyte HIF-1α expression in septic patients, [2] as well as a worse outcome of T-allele carriers with metastatic prostate cancer [6]. The gene discussed is HIF1A; the disease is metastatic prostate carcinoma.